Clearance from the FDA to begin Phase I trials comes 30 days after submitting an IND. We saw two or three weeks ago that NuGenerex/Generex signed an agreement with a CRO to oversee the human trials. What I’m hoping is that what is quiet now is robust and loud soon. IND not only submitted but approved, Principal Investigator and CRO set up sites quickly, first patient dosed with Ii-Key SARS Covid peptide vaccine, etc.